建立和验证非小细胞肺癌PD-1/PD-L1抑制剂相关不良反应的风险预测模型

Tumor immune checkpoints and their associated inhibitors

(2022) Zerui Gao et al.   Journal of Zhejiang University-SCIENCE B

Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

(2021) Carlos Zamora et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis

(2021) Qin Wang et al.   Frontiers in Immunology

Risk factors for immune‐related adverse events from anti‐PD ‐1 or anti‐ PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

(2021) Yiqing Huang et al.   INTERNATIONAL JOURNAL OF CANCER

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

(2020) Lihong Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis

(2020) Mitchell S von Itzstein et al.   CLINICAL CHEMISTRY

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

(2020) Alessio Cortellini et al.   EUROPEAN JOURNAL OF CANCER

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

(2020) Denis Maillet et al.   EUROPEAN JOURNAL OF CANCER

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients

(2020) Peng Song et al.   Thoracic Cancer

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

(2019) Alessio Cortellini et al.   Clinical Lung Cancer

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab

(2019) Yeonghee Eun et al.   Scientific Reports

Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma?

(2018) Graham Pawelec   CLINICAL CANCER RESEARCH

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

(2018) Curtis H. Kugel et al.   CLINICAL CANCER RESEARCH

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Monitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer

(2016) Grainne M. O'Kane et al.   ONCOLOGIST

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy

(2015) Harold F. Dvorak   CANCER JOURNAL

Obesity and cancer immunotherapy toxicity

(2015) Annie Mirsoian et al.   Immunotherapy

Platelets in cancer metastasis: To help the “villain” to do evil

(2015) Nailin Li   INTERNATIONAL JOURNAL OF CANCER

Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma

(2014) B. Hu et al.   CLINICAL CANCER RESEARCH

The immune system and aging: a review

(2013) Camil Castelo-Branco et al.   GYNECOLOGICAL ENDOCRINOLOGY

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE